These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31765366)

  • 1. Venous Thromboembolism and Sarcoidosis: A Case Report.
    Arab TM; Decter ER; Ullah T; Thurm CA
    Am J Case Rep; 2019 Nov; 20():1745-1749. PubMed ID: 31765366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
    Minami K; Kumagai K; Sugai Y; Nakamura K; Naito S; Oshima S
    Intern Med; 2018 Jul; 57(14):2025-2028. PubMed ID: 29526957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of venous thromboembolism in a 22-year-old woman taking an oral contraceptive pill.
    Shafran DM; Wu C
    CMAJ; 2017 Nov; 189(47):E1459-E1460. PubMed ID: 29180385
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
    Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
    Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.
    Krause M; Henningsen A; Torge A; Juhl D; Junker R; Kenet G; Kowalski D; Limperger V; Mesters R; Anonymous ; Rocke A; Shneyder M; Clausnizer H; Schiesewitz H; Nowak-Göttl U
    Thromb Res; 2016 Dec; 148():145-151. PubMed ID: 27687905
    [No Abstract]   [Full Text] [Related]  

  • 7. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.
    Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB
    Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease.
    Theberge I; Bowdridge J; Forgie MA; Carrier M; Louzada M; Siquiera L; Rhodes M; Wells PS
    Thromb Res; 2017 Apr; 152():4-6. PubMed ID: 28192715
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
    Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
    Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of rivaroxaban starter packs on emergency department throughput.
    Ayers GT; D'Amico PhD F; Farrah RM; Klatt PM; Baumgartner MA
    Am J Emerg Med; 2018 Sep; 36(9):1698-1699. PubMed ID: 29429797
    [No Abstract]   [Full Text] [Related]  

  • 14. Eosinophilic granulomatosis with polyangiitis followed by venous thromboembolism resulting in severe cutaneous ulcers.
    Ogawa T; Okiyama N; Koguchi-Yoshioka H; Fujimoto M
    J Dermatol; 2017 Sep; 44(9):e216-e217. PubMed ID: 28556974
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association of sarcoidosis and Takayasu's arteritis: an additional case report].
    Robaday S; Hervé F; Cailleux N; Dominique S; Levesque H; Marie I
    Rev Med Interne; 2005 Oct; 26(10):816-9. PubMed ID: 16023270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
    Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.